Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

DAT regimen

Known as: Daunorubicin-AraC-Thioguanine Regimen, Daunorubicin-Cytarabine-Thioguanine Regimen, MRC AML10 Study-DAT Regimen 
A regimen consisting of daunorubicin, cytarabine (Ara-C) and thioguanine, used as an induction treatment for childhood acute myeloid leukemia (AML).
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The prevalence of type 2 diabetes mellitus (T2DM), which leads to diabetic complications, has been increasing worldwide. The… Expand
Highly Cited
2014
Highly Cited
2014
Individuals with bipolar disorder (BD) exhibit deleterious decision making, negatively impacting their lives. Such aberrant… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2013
2013
Direct antiglobulin test (DAT)‐negative (DAT‐)autoimmune hemolytic anemia (AIHA) is empirically thought to show the same clinical… Expand
2012
2012
Social anxiety disorder (SAD) is characterised by fear of social or performance situations where the individual is exposed to… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2011
Highly Cited
2011
Reduced functioning of the dopamine transporter (DAT) has been linked to bipolar disorder (BD). Mice with reduced DAT functioning… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
2006
2006
The expression of the dopamine plasma membrane transporter (DAT) was investigated in rat thymus and spleen by immunochemical and… Expand
2005
2005
This thesis deals with the problem of seam detection for robotic laser welding applications. Within the Mechanical Automation… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 3
Highly Cited
1990
Highly Cited
1990
n a The existing Carrier Sense Multiple Access (CSMA) method widely used i mateur packet radio on shared simplex packet radio… Expand
  • figure 1
  • figure 1
  • figure 3
  • figure 4
1988
1988
Thirty-five patients with acute myelogenous leukemia were treated with aclacinomycin A (60 mg/m2/day for 5 days) and VP-16-213… Expand
Highly Cited
1986
Highly Cited
1986
One patient with acute nonlymphocytic leukemia (ANLL) in remission was given intensive chemotherapy (DAT regimen) as late… Expand